Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers

19 Aug 2025

Abstract excerpt

Homologous recombination deficiency (HRD) is a common characteristic of human cancers, which occurs most frequently in ovarian and breast cancers. The unique genetic vulnerabilities, coupled with the synthetic lethality effect of Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPi), provide a promising opportunity for targeting HRD cancers. However, only a few HRD patients benefit from PARPi monotherapy, and it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40830526
DOI: 10.1186/s40364-025-00814-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersPMID 40830526Read ↗

Homologous Recombination Repair Deficiency and Implications for Tumor ImmunogenicitySemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer typesSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

Genomic and molecular landscape of homologous recombination deficiency across multiple cancer typesSemantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

DNA damage response in breast cancer and its significant role in guiding novel precise therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.